卫光生物：披露向特定对象发行股票审核问询函回复及文件更新

Core Viewpoint - The company has received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a specific issuance of A-shares, and it will respond to the questions while updating the relevant application documents [1] Group 1 - The company is working with intermediaries to address the issues raised in the inquiry letter [1] - The financial data in the application documents has been updated in accordance with the disclosure of the Q3 2025 report [1] - The updated documents have been disclosed on the Giant Tide Information Network [1] Group 2 - The issuance of A-shares requires approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1] - The timeline for the final results of the application remains uncertain, and the company will disclose progress in a timely manner [1]